Renal Transplant Rejection
37
1
3
19
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
11 trials with published results (30%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
13.5%
5 terminated out of 37 trials
79.2%
-7.3% vs benchmark
41%
15 trials in Phase 3/4
58%
11 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (37)
Simulect Versus ATG in Sensitized Renal Transplant Patient
Torque Teno Virus: A Biomarker of Immunosuppression
Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes
VIRTUUS Children's Study
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
Heme Arginate in Transplantation Study
Multi-Parametric MRI for Renal Transplantation
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant
Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection
Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation
Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation
Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients
Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection
Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
Urine CXCL10 Chemokine Monitoring Post-renal Transplant
Pathology and Imaging in Kidney Allografts
Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)
Mesenchymal Stromal Cell Therapy in Renal Recipients